QRX003 (via Quoin Pharmaceuticals)
Netherton Syndrome
Clinical TrialsActive
Key Facts
About Skinvisible Pharmaceuticals
Skinvisible Pharmaceuticals is a drug delivery technology company leveraging its proprietary Invisicare® polymer platform to create enhanced topical and transdermal formulations. Its pipeline is strategically focused on dermatology, rare skin diseases, and the high-growth obesity/metabolic health market, aiming to provide needle-free alternatives to injections. The company follows a capital-light, partnership-driven business model, licensing its technology to development and commercial partners, as evidenced by its active collaboration with Quoin Pharmaceuticals for Netherton Syndrome.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| ATR-12 | Azitra | Phase 1 |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| SXR1096 | Sixera Pharma | Phase 1 |
| KB104 | Krystal Biotech | Preclinical |
| BCX17725 | BioCryst Pharmaceuticals | Pre-Clinical/Phase 1 |
| QRX003 | Quoin Pharmaceuticals | Phase 2/3 |